Latest Conference Articles

Celltrion, Samsung Bioepis Unveil New Biosimilar Data in CD, UC at ECCO 2024

Skylar Jeremias

February 23 2024

At the Congress of European Crohn’s and Colitis Organisation (ECCO), Celltrion and Samsung Bioepis presented new finding from their respective biosimilar analyses, demonstrating positive safety and efficacy measures for the biosimilars as treatments for Crohn disease (CD) and ulcerative colitis (UC).

SABCS Posters Review Use of Biosimilars in New Contexts as Breast Cancer Therapy

Skylar Jeremias

January 17 2024

As one study presented at the 2023 San Antonio Breast Cancer Symposium (SABCS) evaluated the use of circulating tumor DNA for response prediction after combination therapy with a trastuzumab biosimilar, another examined the efficacy of a pertuzumab biosimilar candidate.

Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape

Skylar Jeremias

January 14 2024

Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.

Dr Prerakkumar Parikh Reacts to FDA Approvals for First Neurology, Tocilizumab Biosimilars

Brooke McCormick,Skylar Jeremias

January 7 2024

Prerakkumar Parikh, PharmD, director of specialty clinical solutions at Magellan Rx Management, reacts to recent FDA approvals for the first natalizumab and tocilizumab biosimilars.

Posters Show Efficacy for Combination Therapies With Trastuzumab Biosimilars in Breast Cancer

Skylar Jeremias

January 4 2024

Posters from San Antonio Breast Cancer Symposium 2023 found that combination therapies featuring trastuzumab biosimilars and other common cancer medicines were safe and effective in patients with breast cancer.

The Top 5 Most-Read Conference Stories of 2023

Skylar Jeremias

December 28 2023

The top 5 most-read conference stories of 2023 recapped some of big biosimilar takeaways from this year’s conferences, including insight into how geopolitics will impact the industry, efforts from government agencies, and strategies to increase biosimilar uptake.

Q&A: Dr Kimberly Maxfield Explains How BsUFA III Will Advance the US Biosimilar Industry

Skylar Jeremias,Brooke McCormick

December 20 2023

At AMCP Nexus, Kimberly Maxfield, PhD, pharmacologist at the FDA, delved into how the third reauthorization of the Biosimilar User Fee Act (BsUFA III) will shape the American biosimilar market and improve development efficiency over the next few years.

SABCS Posters Evaluate Real-World Outcomes Associated With Ogivri

Skylar Jeremias

December 14 2023

Two Taiwanese posters presented at the San Antonio Breast Cancer Symposium (SABCS) 2023 annual meeting evaluated the real-world implications of using trastuzumab biosimilars, particularly Ogivri (trastuzumab-dkst) in patients with HER2-postive breast cancer.

Panelists Deliberate Strategies to Enhance Biosimilar Integration in Managed Care Spaces

Skylar Jeremias

November 13 2023

At the recent Academy of Managed Care Pharmacy Nexus meeting, panelists discussed the impact of introducing biosimilars in new medical fields, emphasizing the need for more education and collaboration to ensure their smooth integration into health care systems.

Commercial Biosimilar Coverage Is on the Rise, but Preferences Still Vary

Skylar Jeremias

October 28 2023

A poster from AMCP Nexus quantifies trends in biosimilar coverage within Tufts Medical Center, finding that payer coverage of these products has increased but individual preferences among payers still vary.